Aratana Therapeutics, Inc.
PETX
PETX was delisted on the 17th of July, 2019.
105 hedge funds and large institutions have $133M invested in Aratana Therapeutics, Inc. in 2018 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 34 increasing their positions, 27 reducing their positions, and 8 closing their positions.
308% more call options, than puts
Call options by funds: $648K | Put options by funds: $159K
63% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 8
26% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 27
2% more funds holding
Funds holding: 103 → 105 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital invested
Capital invested by funds: $138M → $133M (-$5.62M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
Engaged Capital
Newport Beach,
California
|
+$2.02M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$1.84M |
| 3 |
BlackRock
New York
|
+$1.74M |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
+$851K |
| 5 |
GPGA
Grandeur Peak Global Advisors
Salt Lake City,
Utah
|
+$815K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.1M |
| 2 |
AIC
AWM Investment Company
New York
|
-$2.71M |
| 3 |
Goldman Sachs
New York
|
-$2.19M |
| 4 |
William Blair & Company
Chicago,
Illinois
|
-$1.33M |
| 5 |
Renaissance Technologies
New York
|
-$1.02M |
PETX Hedge Fund Activity: Q2 2018 in Review
105 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q2 2018, worth a combined $133M — down 4.1% from $138M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new PETX positions and 8 closed out — a net gain of 5 holders — while 34 added to existing stakes and 27 trimmed.
The largest buyer was Engaged Capital, adding an estimated $2.02M. The largest seller was Millennium Management, cutting an estimated $4.1M.
- 105 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q2 2018, up from 103 in Q1 2018.
- Funds reported $133M of Aratana Therapeutics, Inc. stock for Q2 2018, down 4.1% quarter-over-quarter.
- 13 funds opened new Aratana Therapeutics, Inc. positions in Q2 2018 and 8 closed out, a net change of +5 holders.
- The largest Aratana Therapeutics, Inc. buyer in Q2 2018 was Engaged Capital, an estimated $2.02M added.
- The largest Aratana Therapeutics, Inc. seller in Q2 2018 was Millennium Management, an estimated $4.1M sold.
Based on aggregated 13F filings for Q2 2018.